Palatin Technologies
147 posts
Palatin Technologies
@PalatinTech
We discover and develop novel therapeutics for patients living with inflammatory and autoimmune conditions. $PTN
Cranbury, NJ Katılım Şubat 2013
120 Takip Edilen828 Takipçiler
💡 Rapid & effective symptom relief for Dry Eye Disease is on the horizon! PL9643 is advancing through Phase 3 trials, bringing us closer to a new therapeutic option. Stay informed: tinyurl.com/PalatinTech
#EyeCare #Innovation #PalatinTech #DED
English
🚨 Breaking News 🚨: FDA confirms the acceptability of Palatin's Phase 3 trials for PL9643 in Dry Eye Disease! 🌟 Strong tolerability & safety profile. A major step forward in eye care innovation. Learn more: tinyurl.com/PalatinTech
#DryEyeDisease #ClinicalTrials #Biotech
English
This study aims to advance obesity treatment by combining our MCR4 agonists with incretin therapeutics. #ObesityTreatment #ClinicalTrials #Biotech #HealthcareInnovation
English
🚀 Palatin Technologies kicks off a Phase 2 obesity study w/ Bremelanotide & Tirzepatide. Learn more: palatin.com/press_releases…
English
🔥 Breaking: Palatin Technologies $PTN reveals positive results from our Phase 3 trial of PL9643 for Dry Eye Disease at ASCRS 2024! 🌐 Quick relief & excellent safety. Dive into the future of eye care with us! 🚀 #EyeHealth #Biotech palatin.com/press_releases…
English
$PTN Vyleesi® (bremelanotide injection) delivers its 7th consecutive quarter of double-digit growth in product revenue and prescriptions dispensed. Prescriptions grew 18% & net product revenue increased 14% over the prior quarter. bit.ly/3ScqRe9
English
We believe the MC4R agonist is the best validated mechanism for adjunctive therapy with GLP-1 agonists and weight loss maintenance. Read the full PR announcement bit.ly/46Yr4FA
English
With the increased use of FDA-approved GLP-1 agonists for treating obesity, there is an unmet need for treatments with alternative mechanisms of action that will help obese patients meet and maintain their weight loss objectives.
English
Excellent safety and tolerability product profile. Potential for PL9643 to address multiple signs and symptoms of dry eye disease.
Learn More: bit.ly/3LluOsv
English
$PTNachieves complete enrollment in Palatin's Phase 3 MELODY-1 study of PL9643 for the treatment of patients with dry eye disease. Topline data is currently expected late 4Q calendar 2023. Interim analysis of the first 120 patients demonstrated:
English
Phase 2 clinical study is expected to commence in 4Q 2023. PDE5i monotherapy in ED patients using Viagra®, Cialis®, or Levitra® accounts for over $4 billion of annual sales in the United States, yet approximately 30%-40% of patients exhibit little or no response.
English
We're staying busy. Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment.
· Palatin successfully co-formulated bremelanotide with a PDE5i. bit.ly/3qrgszw
English